Shockwave, Photobiomodulation, and Physical Therapy for Achilles Tendinopathy

Achilles Tendinopathy Clinical Trial

Official title:

Investigation of the Effectiveness of Shockwave Therapy, Photobiomodulation, and Physical Therapy in the Management of Non-insertional Achilles Tendinopathy

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05751785
• Other study ID #: Photomedicine Project 10
• Status: Active, not recruiting
• Phase: N/A
• Start date: February 13, 2023
• Est. completion date: September 2024

Study information

• Verified date: April 2024
• Source: Musculoskeletal Injury Rehabilitation Research for Operational Readiness
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to learn more about and compare the effectiveness of standard of care (SOC) physical therapy (PT), PT with photobiomodulation therapy (PBMT; low-level laser therapy), PT with shockwave therapy (SWT; high-energy acoustic wave therapy), and PT with PBMT and SWT, to improve function, decrease pain, and resolve symptoms in individuals with non-insertional Achilles tendinopathy. The main question it aims to answer is: • What is the most effective treatment method for non-insertional Achilles tendinopathy? Participants will Researchers will compare PT, PT + SWT, PT + SWT and PBMT to assess the most effective treatment for Achilles tendinopathy.

Description:

Non-insertional Achilles Tendinopathy (AT) is a common overuse injury in adults who are both athletes and nonactive. Tendinopathy occurs when there is either a failed healing response or the failure of normal turnover or remodeling response, and results in pain and limited movement. In the military, lower-extremity injuries due to overuse, (e.g., AT) are the most common category of injuries. The most common treatment of choice for AT is exercise loading programs, however eccentric strengthening (ECC) may only improve symptoms in approximately 60% of patients. Laser-induced photobiomodulation (PBM) has been shown to increase cell proliferation and metabolism, which may aid in the repair and remodeling process. Studies have found that PBM was effective in the treatment of AT. Extracorporeal shockwave therapy (ESWT) is a process in which energy is delivered to the muscles or tendons for pain relief. Current literature supports the use of ESWT as an effective treatment for AT in combination with ECC. Overall, studies indicate that ESWT and photobiomodulation therapy (PBMT) will be effective in treating tendon injuries such as AT, however, these treatment methods have not been evaluated in comparison or combination with each other. The sub-section of AT amongst Active-Duty personnel has very limited research and given the high prevalence, should be addressed. Therefore, our study will compare three different treatment arms utilizing traditional physical therapy (PT), PT plus ESWT, PT plus PBMT, and PT plus ESWT and PBMT. Both self-reported questionnaires and measured outcomes will be used to assess the most effective treatment for AT.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 48
• Est. completion date: September 2024
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• DEERS Eligible
• Between the ages of 18-64
• Currently Active Duty in any of the US Armed Forces
• Clinical diagnosis of mid-portion Achilles tendinopathy (including both unilateral and bilateral) by a healthcare provider based on accepted diagnostic criteria.
• Able to read and understand English language for consent purposes
• Able to commit to 3-weeks of intervention and 6-months of follow-up

Exclusion Criteria:

• Primary insertional Achilles tendinopathy
• Platelet Rich Plasma (PRP), corticosteroid injection, or prolotherapy within 3 months
• Received dry needling within the past 4 weeks
• Previously completed the Silbernagel protocol for Achilles tendinopathy within the past 3 months
• Received SWT within the past 3 months to their Achilles
• Tattoo in the area of treatment (due to sensitivity to PBMT)
• Current use of pacemaker
• Patients with a known underlying cardiac disease that could be affected by SWT
• Patients with neuropathy affecting sensation to pain
• Current use of medications associated with sensitivity to heat or light (e.g. amiodarone, chlorpromazine, doxycycline, hydrochlorothiazide, nalidixic acid, naproxen, piroxicam, tetracycline, thioridazine, voriconazole)
• Current or chronic sciatica (lumbosacral radiculopathy) resulting in chronic or intermittent lower extremity pain, numbness, or tingling.
• Achilles tendon tear or prior Achilles tendon surgery
• Recent lower extremity injury within the last 3 months that required professional medical attention (e.g., ankle sprain, meniscus)
• Concurrent participation in another research study addressing pain issue
• Previously enrolled in the study for contralateral (opposite) leg
• Currently pregnant or plan to become pregnant during intervention period (safety of PBM not established in pregnancy) as determined by hCG urine test
• Diagnosis of rheumatological disease/connective tissue condition, symptomatic arthritis of foot and ankle, a primary running related injury outside of Achilles tendinopathy, or other contraindications to PBMT or SWT

Related Conditions & MeSH terms

• Achilles Tendinopathy
• Tendinopathy

Intervention

Other:
• Physical Therapy
All participants may complete a PT program as standard of care (SOC) treatment addressing individual strength, mobility, and flexibility deficits in both proximal (e.g. spine and hip girdle) along with distal (thigh, leg, and foot/ankle) muscle groups. The provider may also use other modalities to address distal issues. To standardize the loading program, all participants will be given an at-home exercise program designed by Dr. Karin Sibernagel for progressive Achilles tendon loading. The participants will also follow the University of Delaware Return to Sport protocol for return to running. This will be completed alongside the standard of care PT participants will be receiving.

Device:
• Shockwave Therapy
A medical provider will conduct SWT on study participants using the OrthoPlus Ultra 100. This Extracorporeal Pressure Activation Treatment device will be used at a radial shockwave of 3000 counts treatment settings of 15 Hz minimum 2 bars with a focus applicator head at mid-portion of Achilles using clinical focusing technique, and 3000 counts at 15 Hz minimum 2.5 bars using broad oscillator to myotendinous region and over symptomatic areas of gastrocnemius and soleus, treatment will be applied distally to proximally to facilitate lymphatic return adjusting treatment air pressure and amount of force applied by applicator head by patient comfort. The maximum setting for each treatment applicator will be 4 bars of air pressure, and the first 500 counts using each applicator will be applied at 1.5 bars to help desensitize the tissue prior to increasing energy settings. The settings used for each participant will be recorded and followed in a similar approach to treatment.
• Photobiomodulation Therapy
PBMT is delivered with the LightForce® XPi 25W device through the Smart Hand Piece technology. The therapy is transmitted with a rolling glass massage ball at 10 Joules/cm^2 that is applied in a serpentine manner over the site of injury.

Locations

Country	Name	City	State
United States	Madigan Army Medical Center	Tacoma	Washington

Sponsors (3)

Lead Sponsor	Collaborator
Musculoskeletal Injury Rehabilitation Research for Operational Readiness	Fort Belvoir Community Hospital, The Geneva Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Victorian Institute of Sports Assessment - Achilles (VISA-A)	Symptoms severity specific to Achilles will be Victorian Institute of Sports Assessment - Achilles (VISA-A). The VISA-A is currently the only valid and reliable measure to assess function and pain in AT (validity, P<0.01; test-re-test reliability, r = 0.98). Rating scale between 0-10.	Baseline
Primary	Victorian Institute of Sports Assessment - Achilles (VISA-A)	Symptoms severity specific to Achilles will be Victorian Institute of Sports Assessment - Achilles (VISA-A). The VISA-A is currently the only valid and reliable measure to assess function and pain in AT (validity, P<0.01; test-re-test reliability, r = 0.98). Rating scale between 0-10.	3-week
Primary	Victorian Institute of Sports Assessment - Achilles (VISA-A)	Symptoms severity specific to Achilles will be Victorian Institute of Sports Assessment - Achilles (VISA-A). The VISA-A is currently the only valid and reliable measure to assess function and pain in AT (validity, P<0.01; test-re-test reliability, r = 0.98). Rating scale between 0-10.	6-week
Primary	Victorian Institute of Sports Assessment - Achilles (VISA-A)	Symptoms severity specific to Achilles will be Victorian Institute of Sports Assessment - Achilles (VISA-A). The VISA-A is currently the only valid and reliable measure to assess function and pain in AT (validity, P<0.01; test-re-test reliability, r = 0.98). Rating scale between 0-10.	12-week
Primary	Victorian Institute of Sports Assessment - Achilles (VISA-A)	Symptoms severity specific to Achilles will be Victorian Institute of Sports Assessment - Achilles (VISA-A). The VISA-A is currently the only valid and reliable measure to assess function and pain in AT (validity, P<0.01; test-re-test reliability, r = 0.98). Rating scale between 0-10.	6-month
Primary	Lower Extremity Functional Scale (LEFS)	Lower Extremity Functional Scale (LEFS) will capture functional status. Rating scale from 0-4.	Baseline
Primary	Lower Extremity Functional Scale (LEFS)	Lower Extremity Functional Scale (LEFS) will capture functional status. Rating scale from 0-4.	3-week
Primary	Lower Extremity Functional Scale (LEFS)	Lower Extremity Functional Scale (LEFS) will capture functional status. Rating scale from 0-4.	6-week
Primary	Lower Extremity Functional Scale (LEFS)	Lower Extremity Functional Scale (LEFS) will capture functional status. Rating scale from 0-4.	12-week
Primary	Lower Extremity Functional Scale (LEFS)	Lower Extremity Functional Scale (LEFS) will capture functional status. Rating scale from 0-4.	6-month
Primary	Defense and Veteran's Pain Rating Scale (DVPRS)	Defense and Veteran's Pain Rating Scale (DVPRS)will capture pain; basic applied after hop test and supplemental provided at each visit. Rating scale from 0-10.	Baseline
Primary	Defense and Veteran's Pain Rating Scale (DVPRS)	Defense and Veteran's Pain Rating Scale (DVPRS)will capture pain; basic applied after hop test and supplemental provided at each visit. Rating scale from 0-10.	3-week
Primary	Defense and Veteran's Pain Rating Scale (DVPRS)	Defense and Veteran's Pain Rating Scale (DVPRS)will capture pain; basic applied after hop test and supplemental provided at each visit. Rating scale from 0-10.	6-week
Primary	Defense and Veteran's Pain Rating Scale (DVPRS)	Defense and Veteran's Pain Rating Scale (DVPRS)will capture pain; basic applied after hop test and supplemental provided at each visit. Rating scale from 0-10.	12-week
Primary	Defense and Veteran's Pain Rating Scale (DVPRS)	Defense and Veteran's Pain Rating Scale (DVPRS)will capture pain; basic applied after hop test and supplemental provided at each visit. Rating scale from 0-10.	6-month
Primary	University of Wisconsin Running Injury and Recovery Index (UWRI)	The University of Wisconsin Running Injury and Recovery Index (UWRI)will measure aspects unique to returning to running.	Baseline
Primary	University of Wisconsin Running Injury and Recovery Index (UWRI)	The University of Wisconsin Running Injury and Recovery Index (UWRI)will measure aspects unique to returning to running. Rating scale from 0-4.	3-week
Primary	University of Wisconsin Running Injury and Recovery Index (UWRI)	The University of Wisconsin Running Injury and Recovery Index (UWRI)will measure aspects unique to returning to running. Rating scale from 0-4.	6-week
Primary	University of Wisconsin Running Injury and Recovery Index (UWRI)	The University of Wisconsin Running Injury and Recovery Index (UWRI)will measure aspects unique to returning to running. Rating scale from 0-4.	12-week
Primary	University of Wisconsin Running Injury and Recovery Index (UWRI)	The University of Wisconsin Running Injury and Recovery Index (UWRI)will measure aspects unique to returning to running. Rating scale from 0-4.	6-month
Primary	Patient-Reported Outcomes Measurement Information System (PROMIS-29)	Patient-Reported Outcomes Measurement Information System (PROMIS-29) will be used to capture other aspects of non-disease specific measures of health-related domains (physical, mental and social health). Rating scale from 1-5.	Baseline
Primary	Patient-Reported Outcomes Measurement Information System (PROMIS-29)	Patient-Reported Outcomes Measurement Information System (PROMIS-29) will be used to capture other aspects of non-disease specific measures of health-related domains (physical, mental and social health). Rating scale from 1-5.	3-week
Primary	Patient-Reported Outcomes Measurement Information System (PROMIS-29)	Patient-Reported Outcomes Measurement Information System (PROMIS-29) will be used to capture other aspects of non-disease specific measures of health-related domains (physical, mental and social health). Rating scale from 1-5.	6-week
Primary	Patient-Reported Outcomes Measurement Information System (PROMIS-29)	Patient-Reported Outcomes Measurement Information System (PROMIS-29) will be used to capture other aspects of non-disease specific measures of health-related domains (physical, mental and social health). Rating scale from 1-5.	12-week
Primary	Patient-Reported Outcomes Measurement Information System (PROMIS-29)	Patient-Reported Outcomes Measurement Information System (PROMIS-29) will be used to capture other aspects of non-disease specific measures of health-related domains (physical, mental and social health). Rating scale from 1-5.	6-month
Primary	Cross-sectional area	Measures of interest include cross-sectional area. A study team member will assess ultrasound measures at baseline for both limbs, measured in centimeters (cm).	Baseline
Primary	Cross-sectional area	Measures of interest include cross-sectional area. A study team member will assess ultrasound measures at baseline for both limbs, measured in centimeters (cm).	12-week
Primary	Cross Sectional area	Measures of interest include cross-sectional area. A study team member will assess ultrasound measures at baseline for both limbs, measured in centimeters (cm).	6-month
Primary	Width	Measures of interest include width of tendon. A study team member will assess ultrasound measures at baseline for both limbs, measured in centimeters (cm).	Baseline
Primary	Width	Measures of interest include width of tendon. A study team member will assess ultrasound measures at baseline for both limbs, measured in centimeters (cm).	12-week
Primary	Width	Measures of interest include width of tendon. A study team member will assess ultrasound measures at baseline for both limbs, measured in centimeters (cm).	6-month
Primary	Degree of thickening	Measures of interest include degree of thickening of tendon. A study team member will assess ultrasound measures at baseline for both limbs, measured in centimeters (cm).	Baseline
Primary	Degree of thickening	Measures of interest include degree of thickening of tendon. A study team member will assess ultrasound measures at baseline for both limbs, measured in centimeters (cm).	12-week
Primary	Degree of thickening	Measures of interest include degree of thickening of tendon. A study team member will assess ultrasound measures at baseline for both limbs, measured in centimeters (cm).	6-month
Primary	Relative neovascularity	Measures of interest include relative neovascularity. A study team member will assess ultrasound measures at baseline for both limbs. The relative level of neovascularization will be rated from grade 0: no visible vessels, grade 2: 3 to 5 vessels within the region of interest (ROI), grade 3: vessel's in up to 30% of the ROI	Baseline
Primary	Relative neovascularity	Measures of interest include relative neovascularity. A study team member will assess ultrasound measures at baseline for both limbs. The relative level of neovascularization will be rated from grade 0: no visible vessels, grade 2: 3 to 5 vessels within the region of interest (ROI), grade 3: vessel's in up to 30% of the ROI	12-week
Primary	Relative neovascularity	Measures of interest include relative neovascularity. A study team member will assess ultrasound measures at baseline for both limbs. The relative level of neovascularization will be rated from grade 0: no visible vessels, grade 2: 3 to 5 vessels within the region of interest (ROI), grade 3: vessel's in up to 30% of the ROI	6-months
Primary	Elastography	Measures of interest include elastography. A study team member will assess ultrasound measures at baseline for both limbs. The elastography evaluation should be conducted in two orthogonal planes at the area of maximal thickness/width, IAW manufacture guidance on elastography image collections.	Baseline
Primary	Elastography	Measures of interest include elastography. A study team member will assess ultrasound measures at baseline for both limbs. The elastography evaluation should be conducted in two orthogonal planes at the area of maximal thickness/width, IAW manufacture guidance on elastography image collections.	12-week
Primary	Elastography	Measures of interest include elastography. A study team member will assess ultrasound measures at baseline for both limbs. The elastography evaluation should be conducted in two orthogonal planes at the area of maximal thickness/width, IAW manufacture guidance on elastography image collections.	6 Months
Primary	Heel raises-Quantitative function in heel raises to fatigue.	Quantitative function in heel raises to fatigue on both limbs.	Baseline
Primary	Heel raises-Quantitative function in heel raises to fatigue.	Quantitative function in heel raises to fatigue on both limbs.	12-week
Primary	Heel raises-Quantitative function in heel raises to fatigue.	Quantitative function in heel raises to fatigue on both limbs.	6 Months
Primary	Hops	Quantitative function in ankle strength, we will also ask the participants to complete 20 hops and rate their pain using the Defense and Veteran's Pain Rating Scale (DVPRS).	Baseline
Primary	Hops	Quantitative function in ankle strength, we will also ask the participants to complete 20 hops and rate their pain using the Defense and Veteran's Pain Rating Scale (DVPRS).	12-week
Primary	Hops	Quantitative function in ankle strength, we will also ask the participants to complete 20 hops and rate their pain using the Defense and Veteran's Pain Rating Scale (DVPRS).	6 Months
Primary	Ankle range of motion	Quantitative function in range of motion. Ankle- dorsiflexion and plantar flexion range of motion (ROM), both active and passive, will be; measured using a goniometer.	Baseline
Primary	Ankle range of motion	Quantitative function in range of motion. Ankle- dorsiflexion and plantar flexion range of motion (ROM), both active and passive, will be; measured using a goniometer.	12-week
Primary	Ankle range of motion	Quantitative function in range of motion. Ankle- dorsiflexion and plantar flexion range of motion (ROM), both active and passive, will be; measured using a goniometer.	6 Months